Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

14.25
+0.35502.56%
Volume:188.93K
Turnover:2.68M
Market Cap:2.14B
PE:-3.18
High:14.28
Open:14.07
Low:14.07
Close:13.89
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:23.49
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:175.31
PE(LYR):-2.08

Loading ...

Jan 07, 2022

Major Issues Report

8-K - Current report
Dec 30, 2021

Major Issues Report

8-K - Current report
Dec 01, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 26, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 26, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 26, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 26, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 26, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 26, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 12, 2021

Major Issues Report

8-K - Current report
Nov 09, 2021

Major Issues Report

8-K - Current report
Nov 09, 2021

Major Issues Report

8-K - Current report
Nov 09, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 06, 2021

Major Issues Report

8-K - Current report
Oct 01, 2021

Major Issues Report

8-K - Current report
Sep 27, 2021

Major Issues Report

8-K - Current report
Aug 09, 2021

Major Issues Report

8-K - Current report
Aug 09, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 07, 2021

Major Issues Report

8-K/A [Amend] - Current report
Jul 07, 2021

Major Issues Report

8-K - Current report